B Cell Lymphoma
Conference Coverage
DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on
Pending additional follow-up for overall survival, is the extra cost worth it?
Conference Coverage
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphoma
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin...
Conference Coverage
‘Remarkable’ results with CAR T cells could make chemo obsolete
“It’s really remarkable that the results are so far in favor of the CAR T-cell therapy that I think it’s inevitable that this will become the...
From the Journals
In some lymphomas, ibrutinib yields “almost unheard-of” survival rates
Adding ibrutinib to standard chemotherapy improves DLBCL survival in younger patients, especially among certain genetic subtypes.
From the Journals
Easing access to DLBCL treatments: Patient study reveals racial differences
Collaborative follow-up models could improve access to cellular therapies, but more customized strategies are also needed.
Latest News
New trials in lymphoma and MM: Could your patient benefit?
Late-phase clinical trials are opening up, with a chance to enroll one or more of your patients.
From the Journals
On improving DLBCL outcomes, single-agent regimens fall short
Single-agent regimens are most likely not efficient enough to substantially improve outcomes of DLBCL patients.
From the Journals
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignancies
Success of BTKi in treating lymphoid malignancies is marred by resistance
News from the FDA/CDC
FDA grants zanubrutinib an accelerated approval in marginal zone lymphoma
From the Journals
Can reversing T-cell exhaustion benefit in B-cell lymphoma relapse?
News
FDA approves zanubrutinib in Waldenström’s macroglobulinemia